Shanghai Fosun Pharma (Group) Co., Ltd. submitted the latest Monthly Securities Variation Report to Hong Kong Exchanges and Clearing Limited on November 4, 2024, covering data up to October 31, 2024. The report shows that the listed H shares (stock code 02196) on The Stock Exchange of Hong Kong maintained the statutory/registered share capital and issued share quantity at 551,940,500 shares. However, the A-share stock (stock code 600196) experienced a change within this month, with the issued shares decreasing by 1,072,246 shares, resulting in a balance of 2,119,385,965 shares. This change was due to the cancellation of relevant shares on October 8, 2024, as part of the Restricted A-share Stock Incentive Plan approved at the shareholders' meeting on November 29, 2022. The report did not mention any commitment to issue, convertible notes, other agreements or arrangements, and relevant information on Hong Kong depositary securities.

Shanghai Fosun Pharma (Group) Co., Ltd. submitted the latest Monthly Securities Variation Report to Hong Kong Exchanges and Clearing Limited on November 4, 2024, covering data up to October 31, 2024. The report shows that the listed H shares (stock code 02196) on The Stock Exchange of Hong Kong maintained the statutory/registered share capital and issued share quantity at 551,940,500 shares. However, the A-share stock (stock code 600196) experienced a change within this month, with the issued shares decreasing by 1,072,246 shares, resulting in a balance of 2,119,385,965 shares. This change was due to the cancellation of relevant shares on October 8, 2024, as part of the Restricted A-share Stock Incentive Plan approved at the shareholders' meeting on November 29, 2022. The report did not mention any commitment to issue, convertible notes, other agreements or arrangements, and relevant information on Hong Kong depositary securities.